Compare SEM & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SEM | NRIX |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 2008 | 2020 |
| Metric | SEM | NRIX |
|---|---|---|
| Price | $16.27 | $14.81 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $15.17 | ★ $30.58 |
| AVG Volume (30 Days) | ★ 3.1M | 785.4K |
| Earning Date | 04-30-2026 | 04-07-2026 |
| Dividend Yield | ★ 1.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | N/A | ★ $76,987,000.00 |
| Revenue This Year | $5.45 | N/A |
| Revenue Next Year | $4.78 | $26.32 |
| P/E Ratio | $14.02 | ★ N/A |
| Revenue Growth | N/A | ★ 99.31 |
| 52 Week Low | $11.65 | $8.18 |
| 52 Week High | $18.61 | $22.50 |
| Indicator | SEM | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 63.73 | 40.32 |
| Support Level | $16.20 | $11.34 |
| Resistance Level | $16.30 | $16.47 |
| Average True Range (ATR) | 0.04 | 0.81 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 70.00 | 15.86 |
Select Medical Holdings Corp is a healthcare company that operates through three segments: critical illness recovery hospitals, rehabilitation hospitals, and outpatient rehabilitation clinics. Critical illness recovery hospitals which derives maximum revenue consists of hospitals designed to serve the needs of patients recovering from critical illnesses, often with complex medical needs. The rehabilitation hospital segment consists of hospitals designed to serve patients that require intensive physical rehabilitation care. Patients are typically admitted to critical illness recovery hospitals and rehabilitation hospitals from general acute care hospitals. The outpatient rehabilitation segment consists of clinics that provide physical, occupational, and speech rehabilitation services.
Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment.